CVM-1118 plus nivolumab for advanced liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 2 trial tests whether CVM-1118 given with nivolumab can help people with advanced, unresectable hepatocellular carcinoma (a type of liver cancer) that can’t be cured with surgery. It’s for patients whose cancer has worsened after earlier cancer medicines or treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older (age 20 or older in Taiwan).
- You have hepatocellular carcinoma (liver cancer) that is advanced and cannot be removed with curative treatment, and it has progressed after prior systemic cancer therapy or you couldn’t tolerate it.
- Your liver is working well enough for treatment (Child-Pugh class A), and your blood tests (AST/ALT, bilirubin, platelets, blood counts, INR) are within required ranges.
- You can be physically active at a level that matches an ECOG score of 0–1, and scans show measurable disease.
- You have hepatitis B or C (HBV on antivirals with low virus level, or HCV with detectable virus or antibodies).
- You have not had prior immunotherapy for liver cancer (nivolumab is immunotherapy), and you do not have certain recent treatments or complications (like recent major radiation or recent stomach/esophagus bleeding).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether an individualized “neoantigen” cancer vaccine given to immune cells (dendritic cells) plus nivolumab can improve outcomes in people with liver cancer and/or colorectal cancer that has spread only to the liver. It focuses on tumors that can be removed with curative surgery (with or without local ablation) and on people with good enough liver and overall health.
This Phase 2 trial studies whether adding a cancer vaccine (to help the immune system recognize your tumor) to two medicines—atezolizumab and bevacizumab—can better control unresectable or advanced liver cancer. It’s for people who haven’t had prior whole-body (systemic) cancer treatment.
This trial tests combining a special virus injected directly into the tumor with two approved drugs (tislelizumab and lenvatinib) for advanced liver cancer that hasn't been treated before. The goal is to see if this triple approach can shrink tumors and improve outcomes.
This trial tests a combination of immunotherapy (anti-PD-1/PD-L1) and an anti-VEGF drug for people with advanced hepatocellular carcinoma (HCC), a type of liver cancer that cannot be removed by surgery or has spread. The goal is to see if these drugs can shrink tumors or slow the cancer's growth.
This trial tests a new medicine, PF-08634404, alone or with other treatments for adults with advanced liver cancer that cannot be removed by surgery or has spread. It is for people who have not had prior systemic therapy and have good liver function.
This trial compares an immune “checkpoint” medicine to a targeted cancer medicine in people with advanced liver cancer who have hepatitis B in the blood. It aims to lower hepatitis B surface antigen (HBsAg) levels and see which approach works better and is safest.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.